Market Overview

UPDATE: Goldman Sachs Upgrades Laboratory Corp. of America Holdings to Neutral on ACA Tailwinds

Share:
Related LH
Analyst: Future Of Laboratory Corp's Stock Hinges On This
Laboratory Corp Q1 Profit Tops Estimates
Beyond Pharma: 3 Healthcare Choices - Analyst Blog (Zacks)

In a report published Thursday, Goldman Sachs analyst Isaac Ro upgraded the rating on Laboratory Corp. of America Holdings (NYSE: LH) from Sell to Neutral, and raised the price target from $83.00 to $96.00.

In the report, Ro noted, “We now believe LH stands to benefit from a volume tailwind from ACA and pricing pressure should be manageable – driving our more positive outlook on LH shares. However we prefer DGX over LH, as wee see less margin upside and our current estimates already reflect considerably more aggressive share repurchase than DGX limiting upside outer year EPS estimates. Since adding LH to the Sell List on 11/18/12, the shares are +13% vs. the S&P 500 +17% given limited volume growth and pricing pressure. Over the past 12 months, LH is +5% vs. the S&P 500 +17%.”

Laboratory Corp. of America Holdings closed on Wednesday at $93.40.

Latest Ratings for LH

DateFirmActionFromTo
Apr 2015JP MorganMaintainsOverweight
Apr 2015JefferiesMaintainsHold
Mar 2015JMP SecuritiesInitiates Coverage onMarket Outperform

View More Analyst Ratings for LH
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Upgrades Analyst Ratings

 

Related Articles (LH)

Around the Web, We're Loving...